that takes advantage of their finding that human cytomegalovirus (HCMV) is frequently expressed in such tumors (10) .
Can viruses cause brain tumors?
Whether viruses have a causal role in brain tumor development has been hotly debated for decades (11) . Epidemiologic data pointing to a potential role for viruses in the development of brain tumors include several studies reporting an increased risk of developing a childhood brain tumor in individuals whose mothers were infected with various viruses, such as those that cause chicken pox, mumps, and rubella, during pregnancy (12, 13) . However, the largest area of inquiry into the possibility of an infectious etiology of brain tumors comes from studies of polyomaviruses, a genus of viruses that includes simian vacuolating virus 40 (SV40). In vitro, the T antigen encoded by many polyomaviruses readily transforms cells and induces CNS tumors, including medulloblastomas, gliomas, and choroid plexus papillomas, in a variety of animal models (14) . Human studies correlating viruses and brain tumors include epidemiological studies suggesting that polyoma virus-contaminated vaccinations administered to women in the 1950s and '60s were associated with increased risk of brain tumors in their children (15) (16) (17) , and more recently, those indicating the presence of polyoma DNA and protein in human brain tumors, including the detection of polyoma JC virus in medulloblastoma (18) . Despite the spate of early experiments indicating a potential role for polyomaviruses in brain tumor formation, over time it has been difficult, some would say near impossible, to move from correlation to cause in the arena of human brain tumors. Over the years, the literature has been peppered with claims and counterclaims of polyomavirus detection in human tumor specimens (18, 19) , but definitive proof of polyomaviruses causing brain tumors is still not available.
Can viruses be used to treat brain tumors?
The controversy surrounding the potential causal role of viruses in brain tumor development has been swirling for years. More recently, however, interest in viral CNS tumor pathogenesis has yielded to the related field of viral therapy for brain tumors (20) . Oncolytic viral therapy uses replicationcompetent viruses to selectively infect and kill cancer cells while leaving normal, nontransformed cells intact. Viruses used in this way in clinical trials for malignant glial brain tumors include herpes simplex viruses, adenoviruses, reoviruses, and Newcastle disease viruses (20) . Although in trial for malignant gliomas, this strategy has not yet been evaluated for the treatment of medulloblastoma. However, preclinical data exist suggesting that measles virus might be an effective oncolytic virus in individuals with medulloblastoma (21). Studebaker et al. demonstrated that the measles virus receptor CD46
Figure 1
Effect of valganciclovir and celecoxib on medulloblastoma cell lines expressing HCMV proteins as observed by Baryawno and colleagues (10) . Injection of medulloblastoma cell lines expressing HCMV proteins into the flanks of nude mice results in tumors (Control), which are reduced in size following treatment with either valganciclovir, which targets the DNA polymerase during HCMV replication, or the COX-2 inhibitor celecoxib, which prevents HCMV replication by decreasing PGE2 levels. Treatment with a combination of celecoxib and valganciclovir causes a greater reduction in tumor size than either drug alone. LP, HCMV late protein; IE, HCMV immediate early protein.
was expressed in 13 of 13 medulloblastoma samples tested and that exposure to measles virus led to substantial cell death in medulloblastoma cell lines and xenografts (21) . Similar preclinical data suggest that oncolytic viral therapy using myxoma virus (22) Baryawno and colleagues then went on to test whether either ganciclovir, which targets the DNA polymerase during HCMV replication, or the COX-2 inhibitor celecoxib, which prevents HCMV replication by decreasing PGE 2 levels, affected medulloblastoma growth (10) . They found that ganciclovir decreased the clonogenic capacity of HCMVpositive cell lines but had no effect on HCMVnegative lines. This effect was augmented by the addition of celecoxib. While this study did not address these questions, it will be important to test what effect the drugs have on cell growth in vitro, and whether the effects are cytotoxic or cytostatic.
In a flank xenograft model, Baryawno et al. found that medulloblastoma tumor volume could be reduced by approximately 40% in mice treated with either valganciclovir or celecoxib alone, and by 72% with a combined drug regimen (10) . Similar to the in vitro data, HCMV-negative xenografts were not affected by the drug treatment, supporting the hypothesis that the effect was specific to HCMV-positive tumor cells. Future preclinical studies looking at whether this drug treatment can extend the survival of mice in an orthotopic xenograft model and whether these drugs can be effectively combined with other chemotherapeutic agents and/or radiotherapy will be key.
The data presented by Baryawno et al. demonstrating in vivo reduction of tumor size following treatment with valganciclovir and celecoxib (ref. 10 and Figure 1) are intriguing, as they raise a new potential route through which viruses may be exploited to treat brain tumors. The relatively low toxicity and good blood brain barrier penetration of these agents make them attractive for clinical use, eliminating many of the barriers that still face oncolytic viral therapies. However, the claim of Baryawno and colleagues that their observations suggest a pathogenic role for HCMV in medulloblastoma (10) is less well substantiated. As for polyomavirus, a causal role for HCMV in medulloblastoma development has yet to be shown.
Conclusion
Whether viruses are a major cause of brain tumors may never be conclusively determined. However, as shown by Baryawno et al. (10) , we may be able to exploit our knowledge of the presence of viruses and viral antigens in brain tumors to develop novel therapies for these devastating diseases.
